Evidence map›Paper›PMID 28666384›Full record

ArticleToxicological sciences : an official journal of the Society of Toxicology2017

Gut Microbial Transformation of the Dietary Imidazoquinoxaline Mutagen MelQx Reduces Its Cytotoxic and Mutagenic Potency.

Jianbo Zhang, Michael T Empl, Clarissa Schwab, Mostafa I Fekry, Christina Engels, Mirjam Schneider, Christophe Lacroix, Pablo Steinberg, Shana J Sturla

Open access · bronzeAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Toxicological sciences : an official journal of the Society of Toxicology, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 14 papers.

0numbers the graph read from it
0cells of the map it votes in
14citing papers in PubMed
1.8field-weighted citation impact, top 16% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

14 citing papers in PubMed, 34 citations in OpenAlex.

  1. Article
  2. Article
  3. Microbiome research reports · 2024
    Article
  4. Review
  5. Microbiota of the gastrointestinal tract: Friend or foe?World journal of gastroenterology · 2023
    Review
  6. Article
  7. Origin and Fate of Acrolein in Foods.Foods (Basel, Switzerland) · 2022
    Review
  8. Article
  9. Review
  10. Article
  11. Review
  12. Article
  13. Article
  14. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 2 institutions in 3 countries.

Jianbo ZhangDepartment of Health Sciences and Technology, ETH Zurich, 8092 Zürich, Switzerland.
Michael T EmplInstitute for Food Toxicology, University of Veterinary Medicine Hannover, 30173 Hannover, Germany.
Clarissa SchwabLaboratory of Food Biotechnology, Department of Health Sciences and Technology, Institute of Food, Nutrition and Health, ETH Zurich, 8092 Zürich, Switzerland.
Mostafa I FekryDepartment of Health Sciences and Technology, ETH Zurich, 8092 Zürich, Switzerland.
Christina EngelsLaboratory of Food Biotechnology, Department of Health Sciences and Technology, Institute of Food, Nutrition and Health, ETH Zurich, 8092 Zürich, Switzerland.
Mirjam SchneiderDepartment of Health Sciences and Technology, ETH Zurich, 8092 Zürich, Switzerland.
Christophe LacroixLaboratory of Food Biotechnology, Department of Health Sciences and Technology, Institute of Food, Nutrition and Health, ETH Zurich, 8092 Zürich, Switzerland.
Pablo SteinbergInstitute for Food Toxicology, University of Veterinary Medicine Hannover, 30173 Hannover, Germany.
Shana J SturlaDepartment of Health Sciences and Technology, ETH Zurich, 8092 Zürich, Switzerland.
ETH Zurich · CHUniversity of Veterinary Medicine Hannover, Foundation · DE

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The diverse community of microbes present in the human gut has emerged as an important factor for cancer risk, potentially by altering exposure to chemical carcinogens. In the present study, human gut bacteria were tested for their capacity to transform the carcinogenic heterocyclic amine 2-Amino-3,8-dimethylimidazo[4,5-f]quinoxaline (MelQx). Eubacterium hallii, Lactobacillus reuteri, and Lactobacillus rossiae were able to convert MelQx to a new microbial metabolite characterized on the basis of high-resolution mass spectrometry and NMR as 9-hydroxyl-2,7-dimethyl-7,9,10,11-tetrahydropyrimido[2',1':2,3]imidazo[4,5-f]quinoxaline (MelQx-M1), resulting from conjugation with activated glycerol. Acrolein derived from the decomposition of 3-hydroxypropionaldehyde, which is the product of bacterial glycerol/diol dehydratase activity, was identified as the active compound responsible for the formation of MelQx-M1. A complex human gut microbial community obtained from invitro continuous intestinal fermentation was found to also transform MelQx to MelQx-M1. MelQx-M1 had slightly reduced cytotoxic potency toward human colon epithelial cells invitro, and diminished mutagenic potential toward bacteria after metabolic activation. As bacterially derived acrolein also transformed 2 other HCAs, namely 2-amino-1-methyl-6-phenylimidazo[4,5-b]pyridine and 2-amino-3-methylimidazo[4,5-f]quinoline, these results generalize the capacity of gut microbiota to detoxify HCAs in the gut, potentially modulating cancer risk.

Indexed as

Gastrointestinal Microbiome3T3 CellsAnimalsCarcinogensHumansMiceMice, Inbred BALB CMutagensQuinoxalinesSpectrum Analysis2-amino-3,8-dimethylimidazo(4,5-f)quinoxalineCarcinogensMutagensQuinoxalinesacroleindietary carcinogengut microbiotaheterocyclic aminesmetabolism

Identifiers

PMID28666384
PMCPMC5837702
OpenAlexW2724690645

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.